Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$4.06
-0.5%
$6.16
$3.56
$12.92
$229.12M0.68389,782 shs534,043 shs
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$11.94
-1.9%
$12.53
$4.75
$16.90
$280.01M0.7656,379 shs75,913 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$5.23
-2.4%
$6.15
$4.58
$18.56
$261.03M1.81542,140 shs544,242 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$1.29
-5.1%
$1.47
$0.73
$4.27
$81.50M0.79319,706 shs147,537 shs
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-0.49%-21.17%-37.25%-45.50%-63.65%
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-1.89%-8.22%-10.16%+8.55%+99.33%
Cryoport, Inc. stock logo
CYRX
Cryoport
-2.43%-3.86%-21.35%-38.54%-71.14%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-5.15%+0.78%-19.38%+17.27%-66.23%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.2223 of 5 stars
3.63.00.00.02.91.70.0
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
2.093 of 5 stars
3.62.00.00.02.72.50.0
Cryoport, Inc. stock logo
CYRX
Cryoport
2.6649 of 5 stars
3.42.00.00.03.23.30.6
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
1.1308 of 5 stars
3.00.00.00.03.41.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.29
Buy$26.60555.17% Upside
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
3.22
Buy$24.71106.99% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.83
Moderate Buy$11.83126.26% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.00
Hold$11.00752.71% Upside

Current Analyst Ratings Breakdown

Latest GALT, BNTC, CYRX, and ATXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.00
4/10/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/2/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
4/1/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
4/1/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $11.00
3/31/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/24/2025
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/24/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$10.00
3/12/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$27.00 ➝ $28.00
3/11/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$3.33 per shareN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$80K3,500.06N/AN/A$3.24 per share3.69
Cryoport, Inc. stock logo
CYRX
Cryoport
$228.39M1.14$0.31 per share16.95$9.45 per share0.55
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.01) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$72.89M-$1.67N/AN/AN/AN/A-43.58%-29.36%5/8/2025 (Estimated)
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%5/12/2025 (Estimated)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.49N/AN/AN/A-70.08%-13.35%-6.43%5/6/2025 (Estimated)
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$41.07M-$0.76N/AN/AN/AN/AN/A-163.15%5/21/2025 (Estimated)

Latest GALT, BNTC, CYRX, and ATXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.48N/AN/AN/AN/AN/A
5/6/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.28N/AN/AN/A$56.19 millionN/A
3/31/2025Q4 2024
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.16-$0.19-$0.03-$0.19N/AN/A
3/11/2025Q4 2024
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.45-$0.44+$0.01-$0.44N/AN/A
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
2/14/2025Q2 2025
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-$0.55-$0.36+$0.19-$0.33N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
22.38
22.38
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/A
25.48
15.01
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
1.13
1.13

Institutional Ownership

CompanyInstitutional Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
52.19%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%

Insider Ownership

CompanyInsider Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.90%
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
1.30%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.10%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
50.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3056.43 million54.80 millionOptionable
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
2023.45 million23.15 millionNo Data
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02049.91 million44.44 millionOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.18 million31.32 millionOptionable

Recent News About These Companies

HC Wainwright Has Positive Outlook for GALT Q2 Earnings
Research Analysts Set Expectations for GALT FY2029 Earnings
Galectin Therapeutics reports FY24 EPS (76c) vs (74c) last year
Galectin Therapeutics’ belapectin shows reduction in new varices
Galectin Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

$4.06 -0.02 (-0.49%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$4.34 +0.29 (+7.02%)
As of 04/10/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$11.94 -0.23 (-1.89%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$11.89 -0.05 (-0.39%)
As of 04/10/2025 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$5.23 -0.13 (-2.43%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$5.22 -0.01 (-0.19%)
As of 04/10/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$1.29 -0.07 (-5.15%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$1.30 +0.00 (+0.39%)
As of 04/10/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.